ADX-038 for Complement-Mediated Kidney Disease
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 85 (estimated)
- Sponsor
- ADARx Pharmaceuticals, Inc. · Industry
This trial is looking for adults with certain types of kidney diseases. Participants will receive the treatment ADX-038 to help assess its safety and effectiveness.
You may be able to join if
- I have been diagnosed with IgA Nephropathy, C3G, or IC-MPGN.
- My kidney function is stable with an eGFR of 30 mL/min/1.73m2 or higher.
- I have signs of active kidney disease.
- I am currently receiving supportive care as needed.
- I am willing to get required vaccinations.
You may not be able to join if
- I have a hereditary or acquired complement deficiency.
- I have had a kidney transplant or need renal replacement therapy.
- I have a history of solid organ transplant.
- I have other types of kidney disease.
- I have a history of recurrent invasive infections.
- I have received treatments that inhibit complement.
- I have an active systemic viral, bacterial, or fungal infection.
- I have abnormal liver function.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Loading trial locations…